Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors

Yanai, Hidekatsu

doi:10.14740/cr1315

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies using sodium glucose cotransporter 2 inhibitors (SGLT2is) demonstrates that the improvement of eGFR is beneficially associated with the development of CVD in type 2 diabetic patients [ 24 , 25 ], suggesting a significance of effects of drugs on eGFR when managing cardiovascular risks in patients with type 2 diabetes. Considering the impact on eGFR, pemafibrate may be more beneficially associated with the development of CVD as compared with fenofibrate.…”

Section: Discussionmentioning

confidence: 99%

A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients

Yanai¹,

Katsuyama²,

Hakoshima³

2021

Cardiol Res

Self Cite

View full text Add to dashboard Cite

Background Dyslipidemia is one of the major risk factors for cardiovascular disease (CVD), along with hypertension, diabetes, smoking and obesity. Approximately 70% of CVD risk remains even after treatment of elevated low-density lipoprotein-cholesterol (LDL-C) by statins. High triglyceride (TG) and low high-density lipoprotein-cholesterol (HDL-C) level are potential therapeutic targets to prevent CVD. Fibrates were associated with a greater reduction in TG, and a greater increase in HDL-C. Fibrates activate specific transcription factors belonging to the nuclear hormone receptor superfamily, termed peroxisome proliferator-activated receptors (PPARs). Fibrates improve atherogenic dyslipidemia by mediating PPARα. Pemafibrate is a novel member of the selective PPARα modulator (SPPARMα) family that was designed to have a higher PPARα agonistic activity and selectivity than previous fibrates. Here, we aimed to study the influences of the switching from fenofibrate to pemafibrate on metabolic parameters in type 2 diabetic patients. Methods We retrospectively picked up type 2 diabetic patients who had undergone the switching from fenofibrate to pemafibrate, and compared metabolic parameters before the switching with the data at 3, 6 and 12 months after the switching. Results We found 15 patients with type 2 diabetes. Serum alanine aminotransferase significantly decreased at 6 months after the switching as compared with baseline. The estimated glomerular filtration rate (eGFR) significantly increased at 3, 6 and 12 months after the switching from fenofibrate to pemafibrate as compared with baseline. Serum uric acid (UA) levels significantly increased at 3 and 6 months after the switching as compared with baseline. We did not observe changes in other metabolic parameters after the switching. Conclusion We observed a significant increase of eGFR and serum UA after the switching from fenofibrate to pemafibrate in type 2 diabetic patients. Recent evidences suggest that the improvement of eGFR is beneficially associated with the development of CVD in type 2 diabetic patients. Considering the impact on eGFR, pemafibrate may effectively reduce CVD as compared with fenofibrate.

show abstract

Section: Discussionmentioning

confidence: 99%

A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients

Yanai¹,

Katsuyama²,

Hakoshima³

2021

Cardiol Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…14 SGLT2 inhibitors' mechanisms of action of in HF are still a matter of conjecture, even though the drugs exhibit several metabolic, haemodynamic, and organ-specific effects; however, it is unlikely that prevention and treatment of HF are exclusively due to the favourable metabolic and haemodynamic effects. 16,17 Another mode though which SGLT2 inhibitors incite their beneficial effects is by inhibiting of the sodium-hydrogen exchanger (NHE1) activity, which is up-regulated both in T2DM and HF; inhibition of NHE1 receptors provides protection of the heart from toxic intracellular calcium ion (Ca2+) overload. 18 SGLT2 inhibitors may also exert direct effects on myocardial metabolism and decrease myocardial oxidative stress.…”

Section: Introductionmentioning

confidence: 99%

Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events

et al. 2023

View full text Add to dashboard Cite

In modern cardiology, sodium-glucose cotransporter 2 (SGLT2) inhibitors are critical components of heart failure (HF) treatment algorithms and exert their effects primarily by preventing glucose reabsorption and facilitating its urinary excretion. The objective was to systematically review randomized controlled trials (RCTs) assessing the effects of SGLT2 inhibitors, particularly canagliflozin, empagliflozin, dapagliflozin, ertugliflozin, sotagliflozin (dual SGLT inhibitor), and their use in HF. Systematic searches of PubMed/Medline, The Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials. gov databases were performed. There were no restrictions imposed on the date and status of publication; however, there were restrictions on language for the searched studies. A total of 1139 records were identified in the bibliographic searches from both databases and the register of choice for this systematic review. Following duplicate removal, screening for titles and abstracts, and thorough assessment of full-text articles, 12 RCTs met the inclusion criteria. Altogether, 83 878 patients were included in this review. Among the included studies, two RCTs, with six respective reports, investigated canagliflozin, four RCTs with 13 derived reports investigated dapagliflozin, three RCTs with 12 separate reports studied the effects of empagliflozin, one RCT and its three respective reports assessed ertugliflozin's effects, and two RCTs with one added report investigated the dual inhibitor sotagliflozin. Pooled meta-analytic effects of SGLT2 inhibitors were as follows: on atrial fibrillation odds ratio (OR) = 0.

show abstract

Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors

Cited by 2 publications

References 12 publications

A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients

A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients

Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events

Contact Info

Product

Resources

About